Tuesday, December 28, 2010

Ralph Nader -- The Whistle Has Been Blown, But Where's the Enforcement? Drug Industry Fraud

Counter-Punch
December 28, 2010
By RALPH NADER


The corporate defrauding of taxpayers (eg. Medicaid and Medicare) and prescription drugs with skyrocketing prices was the subject of a report by Public Citizen's Dr. Sidney Wolfe and his associates (see citizen.org).

Dr. Wolfe's team compiled a total of 165 federal and state settlements since 1991 totaling $19.8 billion in penalties. A key finding is that the drug industry's penalties under the Federal False Claims Act exceed even those assessed against the overcharging defense industry for fraud.

Before we become overly impressed with the cumulative amount of the penalties, specialists in corporate crime law enforcement believe that adding more federal cops on the corporate crime beat, backed by a determined law and order Justice Department with White House backing, would have greatly increased the number of cases and imposition of penalties on these drug industry giants.

Nonetheless, Dr. Wolfe's study shows that the pace of penalties has picked up over the past five years. This is due to "a combination of increased violations by companies and increased law enforcement on the part of federal and state governments," says the report.

Many of these cases were initiated by company whistleblowers, who under the False Claims Act can receive a share of the settlements. Since the corporate bosses of these drug firms are almost never prosecuted, what these executives fear the most are company employees who go public with the evidence of corporate misdeeds.

These violations do more than financial damage to consumers and government health insurance programs. One of the worst violations involves companies promoting unproven, often dangerous uses for their medicines. Last year, Pfizer paid $1.2 billion for illegal off-label promotion -the largest criminal fine in U.S.history. Other major corporate violators were GlaxoSmithKline, Eli Lilly, Schering-Plough, Bristol-Myers Squibb, AstraZeneca, TAP Pharmaceutical, Merck, Serono, Purdue, Allergan, Novartis, Cephalon, Johnson & Johnson, Forest Laboratories, Sanofi-aventis, Bayer, Mylan, Teva and King Pharmaceuticals.

The violations by these and other drug companies point to the wide range of impacts, including taking many lives of patients, which stems from these recurrent activities. These criminal or civil illegalities cover (1) overcharging government health programs, (2) unlawful promotion, (3) monopoly practices, (4) kickbacks, (5) concealing study findings, (6) poor manufacturing practices, (7) environmental violations, (8) financial violations and (9) illegal distribution.

Outside the purview of the Public Citizen study are the ravages of counterfeit drugs and poorly inspected ingredients in drugs, now mostly coming from China and India, due to the outsourcing by U.S. and European drug companies in their thirst for even greater profits.

Drug company sales are huge, growing from $40 billion in 1990 to $234 billion in 2008, and far exceeding inflation with their annual price gouging. To make matters worse, in 2003, the Congressional Republicans, with decisive support from some Democrats, passed the drug benefit bill which explicitly prohibited Uncle Sam, the payer, from bargaining for volume discounts with drug companies.

With over 400 full-time drug company lobbyists putting pressure on Congress, and tens of millions of dollars flowing into the legislators' campaign coffers, budgets for federal investigators, prosecutors and inspectors are kept to a minimum. Unfortunately, crime in the suites pays over and over again, despite occasional penalties.

A bright spot is the increasing enforcement action at the state level.

By last year, 32 states had enacted false claims acts, including fourteen states that qualified as strong laws by federal standards.

Still, the Wolfe report concludes that the "current system of enforcement is not working." He gives the examples of the $7.44 billion in financial penalties assessed over the past twenty years on GlaxoSmithKline and Pfizer, as compared to their combined total of $16.5 billion in global net profits in one year alone.

What would deter these illegal practices and risks to public safety? Dr. Wolfe says "the lack of criminal prosecution that would result in jailing of company executives." is key. Moreover, the report notes that "a felony conviction could result in their companies becoming ineligible for reimbursement from federal and state health programs, a critical source of pharmaceutical company revenues."

A flicker of hope that a little change is on the way came from the Food and Drug Administration's Deputy Chief Counsel for Litigation, Eric Blumberg. He indicated that the government is considering going after drug company executives for violations such as off-label promotions. He stated: ".unless the government shows more resolve to criminally charge individuals-at all levels in the corporate hierarchy--.we can not expect to make progress in deterring off-label promotion."

The problem is that the final operating decision is in the hands of the Justice Department-historically short-staffed and short-willed to entreaties for prosecution by the FDA and other regulatory agencies.

Furthermore, for over 30 years, the Justice Department has stone-walled requests that it start a corporate crime database as it has done with street crimes. Congress likes it this way, as it continues to cash corporate campaign checks.

Just last week, however, outgoing Judiciary Committee Chairman, Democrat John Conyers introduced a bill (H.R. 6545) to create such a corporate crime data base in the Justice Department. Well, as the saying goes, everything starts with a gesture!

Ralph Nader is the author of Only the Super-Rich Can Save Us!, a novel.

Labels: , , , , , , , , , , ,

Monday, December 13, 2010

A Legacy of Unintended Side Effects

The Boston Globe
Patricia Wen
Dec 12, 2010


First in a three-part series.

Geneva Fielding, a single mother since age 16, has struggled to raise her three energetic boys in the housing projects of Roxbury. Nothing has come easily, least of all money.

Even so, she resisted some years back when neighbors told her about a federal program called SSI that could pay her thousands of dollars a year. The benefit was a lot like welfare, better in many ways, but it came with a catch: To qualify, a child had to be disabled. And if the disability was mental or behavioral — something like ADHD — the child pretty much had to be taking psychotropic drugs.

Fielding never liked the sound of that. She had long believed too many children take such medications, and she avoided them, even as clinicians were putting names to her boys’ troubles: oppositional defiant disorder, depression, ADHD. But then, as bills mounted, friends nudged her about SSI: “Go try.’’

Eventually she did, putting in applications for her two older sons. Neither was on medications; both were rejected. Then last year, school officials persuaded her to let her 10-year-old try a drug for his impulsiveness. Within weeks, his SSI application was approved.

“To get the check,’’ Fielding, 34, has concluded with regret, “you’ve got to medicate the child.’’

There is nothing illegal about what Fielding did — and a lot that is perhaps understandable for a mother in her plight. But her worries and her experience capture, in one case, how this little-scrutinized $10 billion federal disability program has gone seriously astray, becoming an alternative welfare system with troubling built-in incentives that risk harm to children.

A Globe investigation has found that this Supplemental Security Income program — created by Congress primarily to aid indigent children with severe physical disabilities such as cerebral palsy, Down syndrome, and blindness — now largely serves children with relatively common mental, learning, and behavioral disorders such as ADHD. It has also created, for many needy parents, a financial motive to seek prescriptions for powerful drugs for their children.

And once a family gets on SSI, it can be very hard to let go. The attraction of up to $700 a month in payments, and the near-automatic Medicaid coverage that comes with SSI approval, leads some families to count on a child’s remaining classified as disabled, even as his or her condition may be improving. It also leads many teenage beneficiaries to avoid steps — like taking a job — that might jeopardize the disability check.

The latest federal statistics, obtained by the Globe through a public records request, show a stunning rise over the past two decades in the number of children who qualify for SSI because of a variety of mental disabilities.

Of the 1.2 million low-income children nationwide who received SSI checks last year, 53 percent, or 640,000, qualified because of mental, learning, or behavioral issues, up from 8 percent in 1990. By significant margins, the top two disorders are Attention Deficit Hyperactivity Disorder, or ADHD, and delayed speech in young children, followed by autism spectrum disorders, bipolar illness, depression, and learning problems, according to the Social Security Administration, which runs this program and the $55 billion SSI system for adults.

In New England, the numbers are even higher — 63 percent of children qualify for SSI based on such mental disabilities. That is the highest percentage for any region in the country. And here and across the nation, the SSI trend line is up, with children under 5 the fastest-growing group. Once diagnosed, these children often bring in close to half their family’s income.

“This has become the new welfare,’’ said MIT economics professor David Autor. “This is a very valuable resource to families, but you’re providing incentives for them to produce a diagnosis for their children to be part of this program, and there’s also incentives to medicate them. This is a substantial public policy problem.’’

This transformation of the children’s SSI program is viewed as a victory by many disability and mental health advocates, who have long pressed for serious cases of depression and learning disorders to be recognized alongside cerebral palsy and Down syndrome as major disabilities. The program’s expansion has also undoubtedly helped many new families cope with the exhausting needs of deeply troubled children.

“A few years ago, we never saw a bipolar diagnosis in a child; now we do,’’ said David Rust, a top Social Security official who defended the agency’s handling of the SSI children’s program in an interview with the Globe. “The world is changing in terms of who we serve and the kinds of conditions we see.’’

But, the Globe review found, the changing nature of the SSI program has had some disturbing side effects. Many cash-strapped parents have come to believe that if only they can muster the necessary array of medical records, their children have a good shot at this benefit, even if it means carrying the stigma of the word “disabled.’’ And while some parents see their children’s behavior improve from psychotropic drugs — as has been the case so far with Fielding’s youngest boy — they bristle at the outsize role that these medications seem to them to play in securing SSI approval.

For many, the motivation to apply comes down to economics: SSI payments can be a lifeline in a bad economy, and they beat welfare checks in almost every way. For a Massachusetts parent with two children, welfare pays a maximum of about $600 a month. If one of those two children is approved for the SSI program, the total government benefit can be twice as much.

“Everybody’s poor, everyone’s got issues,’’ Fielding said, as she sat in her family’s apartment near Madison Park. “People are going to try to get a check.’’

Learning the system At the beginning of every month, postal carriers drop more than 21,000 SSI checks on behalf of children into mailboxes across Massachusetts, mostly in distressed areas of Springfield, Boston, Holyoke, Lawrence, and New Bedford. Only youngsters living around the poverty level are financially eligible, and many of their parents, out of work or maxed-out on welfare benefits, have grown resigned to homeless shelters and food pantries.

The children on SSI represent a cross section of the poor. Federal data show that roughly half identified as white, half as black; some 16 percent self-identified as Hispanic. Two of every three recipients are boys, in part because ADHD diagnoses skew heavily male. And ADHD is the top diagnosis, constituting 31 percent of all children on SSI for behavioral, learning, and mental disorders.

As the Globe investigated the surge in SSI cases — mostly by visiting housing projects, Social Security offices, and downtown districts — many parents were reluctant to talk, fearful of losing this coveted benefit. Still, some two dozen families agreed to be interviewed, in part to vent their frustration at what they perceive to be the government’s arbitrary approval process in mental disability cases. Some wanted only their first names to be used as they described their persistent efforts to figure out what Social Security wanted, and their growing conviction that medication for the child was a critical step.

Waiting on a bench in a rundown commercial strip of Lawrence, Yessenia was among the frustrated.

The 28-year-old woman said late last summer that she will be trying, for the third time, to obtain SSI payments for her 7-year-old son based on his ADHD symptoms: impulsivity and inattention.

Yessenia said she is convinced her son’s first two applications were rejected because she had nothing to list in the section labeled “medications.’’ But in recent months, she has convinced the boy’s doctor to write a prescription. Her son is now taking a stimulant often used for ADHD.

“If you child doesn’t have medications, the SSI office thinks he doesn’t have any big problem,’’ she said.

Yessenia and her extended family have long experience with the SSI program. As a child, she said, she qualified for SSI based primarily because of learning disabilities, and after her 18th birthday, she requalified as an adult on the same basis. Her older sister, diagnosed with bipolar disorder, has been receiving SSI benefits since childhood.

Yessenia said she has other reasons to be optimistic that her son’s new application will be approved.

“Since he was denied all the time, the therapist said she’d give him another diagnosis, and that’s when she said he’s got depression,’’ said the mother, who has yet to submit the new application. “She’s also recommending another drug.’’

Yessenia, and the others interviewed, insisted that they do only what is best for their children’s health and would never medicate purely to boost their SSI application. But some of the parents said they know of others who exaggerate their children’s symptoms so that clinicians prescribe medications or add additional psychiatric diagnoses.

“A lot of people do it,’’ said Makeysha, a Jamaica Plain mother whose child is on SSI for ADHD. “A lot of people don’t have income coming in.’’

A special education teacher at Holyoke High School with two decades of experience said it is clear to her that indigent parents learn, through word of mouth, the strategic “ins and outs’’ of the SSI system. The teacher, who asked not to be named because she is not authorized to speak about student records, said she has seen hundreds of teenagers on SSI for mental disabilities.

“I don’t know anyone who isn’t on drugs,’’ she said.

She also said she is frequently asked by parents to complete SSI paperwork about a child’s academic level, in hopes that it will confirm a diagnosis for some kind of mental disorder.

A horrifying case The incentives built into the SSI program and their potential hazards came into starkest relief in the case of a South Shore couple, Carolyn and Michael Riley.

Their story was horrifying and far from typical, but also telling about how a child’s mental health diagnosis can be abused in the name of money.

Each of their three children was, according to medical records, diagnosed with ADHD and bipolar disorder, and prescribed three powerful drugs. The parents made sure to highlight the youngsters’ prescription data in their SSI applications: “If not for medication, my son would not be able to sleep more than 3 hours in a 24-hour period,’’ Michael Riley wrote. The parents obtained SSI benefits for the oldest two children, and for themselves through the SSI program for adults. They were applying for benefits for 4-year-old Rebecca, when the girl turned gravely ill sometime after midnight on Dec. 13, 2006.

Rebecca had been sick with an respiratory infection, but the Rileys did not take her to a doctor. Instead, they fed her excessive amounts of clonodine, a sedating medication often prescribed for ADHD, to get her to sleep. She ultimately died of a drug overdose, and jurors this year convicted her parents of killing Rebecca with their reckless care. Records made public during the murder trials showed the parents’ casual approach to medication over years, and how their calculated pursuit of SSI checks and psychiatric pills caused them to exaggerate their children’s behaviors to clinicians, including a Tufts Medical Center psychiatrist.

Until the day Rebecca died, the family depended largely on SSI checks totaling roughly $30,000 a year.

As extreme as their case proved to be, the way this family sustained itself financially is far from rare. As more families are cut off from the nation’s welfare benefits, millions of indigent parents have turned to SSI.

Said Williams College economist Lucie Schmidt: “It’s become the de facto backup safety net.’’

Top officials in the Social Security Administration, in an interview this fall at the agency’s headquarters just outside Baltimore, insisted they do their best to implement the Congressional mandates for the SSI children’s program, which require sensitivity to a wide range of physical and mental disabilities, while approving only those children with severe impairments.

Art Spencer, associate commissioner in the agency’s office of disability programs, said he was disturbed to hear that the Globe’s review found that many indigent families are convinced that psychotropic drugs are critical in obtaining SSI benefits.

“Medication helps confirm a diagnosis, but most of the decision is going to be based on the child’s function,’’ said Spencer, whose agency’s primary job is overseeing the nation’s $800 billion program for retirees’ and other workers’ benefits.

Rust, deputy commissioner in the office of retirement and disability policy, said each child’s case is carefully reviewed by a disability examiner, as well as an in-house pediatrician.

He said that the agency does not currently track how many children on SSI are prescribed psychotropic medications, but that a new computerized record-keeping system may give them the ability to do so. Rust emphasized that, ultimately, awarding benefits rests largely on what the child’s doctors and clinicians say about the child’s impairment, and that the agency needs to trust that information. He said, on occasion, disability officials have spotted clusters of SSI families with the same doctors, and with strikingly similar diagnosis and treatments, and referred those for possible fraud prosecution. But mostly, he said, “We work off the medical evidence we get.’’

Rust, a former high school teacher, acknowledged, however, the risk that long-term SSI enrollment may exact a psychic toll.

“One of my concerns about the program is that by designating a child as being disabled, it creates a certain mindset with the child, with the family, with the schools… . You’re disabled. You are unable to do certain things,’’ he said. “I really do wor ry, in the program’s attempt to help children, and that’s what we’re trying to do, we can create a certain psychology of disability that is hard to break. ’’

A subjective scale It is easy to see why indigent families are confused by eligibility rules — and looking for a shortcut to SSI approval.

On paper, the eligibility requirements are daunting. According to the most recent Social Security rules, passed in 1996, a child can be approved for mental disability benefits only if he or she has a “medically determinable impairment that results in marked and severe functional limitations.’’ The impairment should be one that persists for at least a year or may result in death.

In some instances, a specific diagnosis for a severe condition — schizophrenia, for example — is a virtual and uncontroversial guarantee of benefits. But most diagnoses are not of that severity and SSI approval hinges on the highly subjective determination of whether a child’s condition, or cluster of conditions, amounts to a “severe’’ impairment.

Officials wade through piles of medical, clinical, pharmacy, and school records, some haphazardly or partially completed, to determine how a child functions in six designated “domains,’’ such as how well he or she communicates, or gets along with peers, or can take care of his or her own basic needs. One “marked’’ impairment is not enough for SSI approval, but a “severe’’ impairment in one domain, or, alternatively, “marked’’ impairments in two domains, is.

Officials may also rely on standardized neuropsychological and other tests or hire an independent medical expert to evaluate the child. Nevertheless, in many cases, diagnoses are based largely on a parent’s account, and disability evaluators never meet the child face-to-face.

Jennifer Erkulwater, a coauthor of the Harvard University Press book “Medicating Children,’’ about the rise of ADHD diagnoses nationwide, said it is easy to see how psychotropic drugs have turned into a potential marker of a mental disorder’s severity.

“If the doctor says it’s serious, he’s giving a prescription,’’ said Erkulwater, a political science professor at the University of Richmond.

She said it is unclear whether the SSI approval process is a factor behind federal data showing that indigent children are diagnosed and prescribed psychiatric drugs at a higher rate than more well-off children. A 2008 study found, for example, that 12 percent of children on Medicaid were diagnosed with ADHD, compared with 8 percent of children on private insurance. Other national studies using Medicaid data have found that poorer children with behavioral and mental diagnoses are also medicated with ADHD drugs and antipsychotic medications at higher rates.

Erkulwater said researchers have cited many explanations for this difference, including the possibility that doctors are more inclined to medicate poor children or that higher rates of mental disorders exist among the destitute. She said that “among the nexus of reasons’’ is that indigent families may be more open to psychotropic drugs if they believe a prescription will help a child’s SSI application.

Patrisha Thompson, a Fall River mother of two, cited another reason why poor families may be quicker to medicate their children for behavioral problems: They don’t have the time for bus or subway rides to talk-therapy sessions, and they know that counseling sessions are unlikely to impress a disability examiner.

Thompson, 28, said her job in the health care industry made her realize the importance of trying behavioral therapy. She took her sons to such sessions before agreeing reluctantly last year to let her sons start a prescription of an ADHD medication. She has since put in SSI applications for both boys, ages 7 and 10, whose diagnoses also include depression, anxiety, and learning disorders. But many indigent parents, she said, do not realize that there are alternatives to drugs, or don’t have the time to pursue them.

“It’s easier to medicate,’’ said Thompson, recounting what she hears from other parents.

Thompson is still waiting to hear how SSI rules on her oldest boy’s application. Her 7-year-old boy was denied, she said, adding that she was not given a reason.

She said the denial may indicate that drugs are not a decisive factor. But she said that, based on her knowledge of other cases, an application with no mention of drugs has “little to no chance’’ of success. Even if both sons’ applications are denied, she said, she is grateful that her job gives her enough income to provide the basics. But she can understand why others, more impoverished, seek SSI approval.

“Money determines everything,’’ she said. “It determines how much you eat, what you eat, and how you treat your kids.’’

Landmark ruling The federal disability program for poor children was born four decades ago, shortly after Congress rejected President Nixon’s groundbreaking 1969 proposal for a guaranteed minimum income for the poor.

Instead, as a compromise of sorts, federal lawmakers approved the Supplemental Security Income program for the elderly, as well as for blind and disabled adults. Some early drafts of the proposal made no mention of children. But at the 11th hour, and virtually as a footnote, lawmakers in 1972 designated disabled children eligible for SSI payments.

The idea was that the benefit would help replace wages lost by indigent parents as they took time out to care for children with severe physical and congenital disabilities, such as cerebral palsy, muscular dystrophy, and deafness, or those with life-threatening illnesses, such as cancer. The money was also seen as a way to help families with extra expenses, such as wheelchairs or taxi rides to hospitals.

It remained for many years a relatively small, highly restrictive program; as late as 1990, it served fewer than 300,000 children, and only 8 percent qualified based on behavioral or mental disorders.

Then, after a landmark legal ruling, the ground began to shift.

The case grew out of a campaign in the early 1980s under President Reagan to reduce SSI rolls. Social Security officials, responding to the new mandate, cut off Brian Zebley, a boy who had been receiving benefits since he was toddler, ruling that he was no longer disabled despite a variety of physical and intellectual disabilities. His family’s lawyer challenged the fairness of the eligibility rules, arguing they were too adult-oriented and rigid, and in 1990, the US Supreme Court agreed. Social Security authorities then rushed to implement new, looser rules, and also widened eligibility for children’s behavioral and learning disorders.

A subsequent spike in mental disability cases led to a national uproar. Media accounts described parents coaching their children to misbehave or flunk tests. Some of those who desired change wanted ADHD cut from the list of allowed SSI diagnoses, arguing that the condition was not typically severe, and that its inclusion was leaving the system vulnerable to an explosion of claims. But they were drowned out by advocates for the disabled. Meanwhile, some federal authorities raised concerns about the program’s potential to harm children.

“Here the moral hazard is that the family may become dependent on SSI, and in order to continue to receive payments, decline to seek treatment aggressively or fail to encourage a child to do his or her best to overcome a disability,’’ said Jim Slattery, a former congressman and chairman of the National Commission on Child Disability, during a 1995 hearing.

By the mid-1990s, federal lawmakers were cracking down.

Congress passed tougher standards for SSI mental disability disorders, saying a child now had to exhibit a “medically determinable’’ disability with “marked and severe’’ limitations. These changes were included as part of sweeping 1996 welfare reforms.

The children’s SSI disability rolls instantly shrunk — but the decline would be short-lived. Families and clinicians began to adjust to the new rules, which emphasized extensive medical records for any claimed disability. From 1997 to 2007, the number of children who qualified under behavioral, mental, and learning disorders more than tripled from 180,000 to 562,000. By last year, more than 639,000 children were on SSI, 53 percent of all cases.

This abrupt climb in cases is a sign, some researchers say, that the SSI program has veered far from its original purpose.

Dr. James Perrin, a Massachusetts General Hospital pediatrician who has served on federal panels evaluating the SSI program, defended the program, saying it cares for many of the most vulnerable youngsters. One of SSI’s main benefits, he said, is providing near-automatic Medicaid coverage for disabled children. But he said some aspects of the program may need to be reconsidered, including the no-strings-attached cash benefit.

“Families with children with disabilities have real needs for additional income - but perhaps that money should be linked to meeting the specific needs of the child’s disability and, where possible, to supporting that child’s transition to productive adult life.’’

‘Driven by the dollar’ The pressure on medical professionals to help families make the case for SSI approval can be considerable.

One nurse practitioner in a large urban clinic who asked to be unnamed because she is not authorized to speak about her patients said she recently faced the wrath of a parent whose 4-year-old child’s SSI benefits, granted at birth due to prematurity, were cut off because the child was much better now. The nurse said she had candidly filled out the SSI form about the child, saying the boy had caught up with his peers and had only “minimal deficits.’’ The mother was livid, shouting at her, “Don’t you think this child’s disabled?’’

“They get angry with us,’’ the nurse practitioner said.

One diagnosis she believes is seriously overused is “the whole vague developmental delay’’ category for young children, often preschoolers who are behaving badly at home or in day care for undetermined reasons. She said clinicians often attribute such behavior to developmental delay, especially if they are sympathetic to that family’s needs for SSI payments.

“It’s all driven by the dollar,’’ she said.

Many doctors, therapists, and social workers say they are well aware of the impact SSI benefits can have on indigent families. Indeed, some clinicians said they often feel pressure to upgrade a diagnosis or tailor the SSI paperwork to increase the odds of approval. Some say they go that extra mile because they believe that furthering the financial stability of needy families is essential in helping a troubled child.

“Some psychiatrists do feel these people are entitled to benefits,’’ said Judy Rolph, a pediatric psychiatric nurse in Boston for more 30 years. “You know these people are poor.’’

Also pushing hard for SSI approvals is the growing number of for-profit firms that specialize in helping poor families tap into SSI benefits. These companies, which call themselves “eligibility service providers,’’ are hired by hospitals, which stand to lose money when caring for uninsured patients. If these firms successfully obtain SSI benefits for an uninsured child, the youngster’s medical bills are paid by Medicaid. The reimbursement rates are even higher if the child is deemed disabled.

Health insurance companies, which administer Medicaid plans, also sometimes hire these firms, for similar financial reasons.

State welfare department officials also often urge poor families to apply for SSI benefits on behalf of their children. There, too, money is the motivation. An indigent child cannot be on both welfare and SSI at the same time, so states save money if a child goes on SSI, which is entirely paid for by federal funds. The cost of traditional welfare is covered by state and federal money.

Such help with the SSI application can be critical for parents, many of whom are at a loss to complete the complex paperwork.

Giselle Cabrera, a family services coordinator at the Head Start preschool in Holyoke, who helps families with SSI applications, sees firsthand how parents struggle to complete certain SSI forms and wonder how candid to be about their children’s symptoms. They are often desperate, she said, and often medication is what they believe will help their child’s case.

“It’s very frustrating for parents,’’ she said.

‘It’s all about surviving’ Sitting in her apartment near Madison Park, Geneva Fielding is surrounded by stacks of well-organized SSI files for her three sons. She continues to be torn about medicating her youngest. Tucked among her thick files is a favorite article, titled, “What if Einstein had been on Ritalin?’’

She acknowledges that her youngest boy is focusing more on his schoolwork, and that doctors say his dosages of Concerta are safe. But still, she says, she wants to stop these drugs as soon as possible. She says she does not worry if her benefits, in the future, are cut.

“God’s been good to me. If they cut me off, I’ll be all right,’’ says Fielding, who is active in parent and neighborhood groups.

As she folds laundry in her three-bedroom apartment, she says she believes her middle child, the 14-year-old, has the greatest mental disabilities. He has been diagnosed with dyslexia, and he struggles with reading. He also has asthma and emotional issues. She worries he will wind up illiterate, like her father. His SSI application has been rejected, but she is appealing.

Fielding says the SSI checks have helped get her through difficult economic times, but she has mixed feelings about the role they play among poor families. She says she decided to speak to the Globe to highlight the worrisome incentive to prescribe children drugs.

“Sometimes I don’t know why we get a check for this,’’ she said, referring to her youngest son’s case. “But if someone says you have ADHD and you’re depressed and you can get a check, they’re going to try to get a check. The poor people will take that every time. It’s all about surviving.’’

Patricia Wen can be reached at wen@globe.com.

Labels: , , , , , , , , , ,

Friday, December 10, 2010

Placebo fraud rocks the very foundation of modern medical science; thousands of clinical trials invalidated

Thursday, October 28, 2010
by Mike Adams, the Health Ranger


(NaturalNews) You know all those thousands of clinical trials conducted over the last few decades comparing pharmaceuticals to placebo pills? Well, it turns out all those studies must now be completely thrown out as utterly non-scientific. And why? Because the placebos used in the studies weren't really placebos at all, rendering the studies scientifically invalid.

This is the conclusion from researchers at the University of California who published their findings in the October issue of the Annals of Internal Medicine. They reviewed 167 placebo-controlled trials published in peer-reviewed medical journals in 2008 and 2009 and found that 92 percent of those trials never even described the ingredients of their placebo pills.

Why is this important? Because placebo pills are supposed to be inert. But nothing is inert, it turns out. Even so-called "sugar pills" contain sugar, obviously. And sugar isn't inert. If you're running a clinical trial on diabetics, testing the effectiveness of a diabetes drug versus a placebo then obviously your clinical trial is going to make the diabetes drug look better than placebo if you use sugar pills as your placebo.

Some placebo pills use olive oil which may actually improve heart health. Other placebo pills use partially-hydrogenated oils which harm heart health. Yet only 8 percent of clinical trials bothered to list the placebo ingredients at all!

Stay with me on this placebo issue... because it gets even more bizarre...

There are no FDA rules regarding placebos in clinical trials

It turns out there are absolutely no FDA rules regarding the choice or composition of placebos used in clinical trials. Technically, a clinical trial director could use eye of newt or lizard's legs as placebo and would not even be required to mention such nefarious details in the trial results. That would cause trouble, trouble, boil and bubble! (Shakespeare reference for all you literary fans...)

We already know that clinical trials are rife with fraud. Most of the clinical trials used by pharmaceutical companies to win FDA approval of their drugs, for example, are funded by pharmaceutical companies. And it is a verifiable fact that most clinical trials tend to find results that favor the financial interests of whatever organization paid for them. So what's to stop Big Pharma from scheming up the perfect placebo that would harm patients just enough to make their own drugs look good by comparison?

Fact: Placebos are usually provided by the very same company funding the clinical trial! Do you detect any room for fraud in this equation?

How drug companies can fake clinical trials with selected placebo pills

Placebo performance strongly influences whether drugs are approved by the FDA, by the way. As the key piece of information on its regulatory approval decisions, the FDA wants to know whether a drug works better than placebo. That's the primary requirement! If they work even 5% better than placebo, they are said to be "efficacious" (meaning they "work"). This is true even if the placebo was selected and used specifically to make the drug look good by comparison.

You see, if there are no regulations or rules regarding placebo, then none of the placebo-controlled clinical trials are scientifically valid.

It's amazing how medical scientists will get rough and tough when attacking homeopathy, touting how their own medicine is "based on the gold standard of scientific evidence!" and yet when it really comes down to it, their scientific evidence is just a jug of quackery mixed with a pinch of wishful thinking and a wisp of pseudoscientific gobbledygook, all framed in the language of scientism by members of the FDA who wouldn't recognize real science if they tripped and fell into a vat full of it.

Big Pharma and the FDA have based their entire system of scientific evidence on a placebo fraud! And if the placebo isn't a placebo, then the scientific evidence isn't scientific.

Oh, but wait. They'll call it science because they wish the placebo to be a placebo. Yep -- the clinical researchers are now psychics, mediums and fortune tellers who simply decree that little pill of olive oil to "be a placebo!" while waving their hands over it in a gesture borrowed from David Copperfield.

James Randi may have never seen a psychic transmute lead into gold, but he's no doubt seen doctors transmute biochemically active substances into totally inert materials merely by wishing them so! It's so amazing!

And this brings me to the really interesting "how-to" part of this article...


How to make your own placebo just like clinical researchers do

Are you wondering how to make your own FDA-approved, scientifically validated placebo? It's easier than you think.

Step 1 - Find something shaped like a pill. It could be a pill full of olive oil, white sugar, palm oil, fluoridated water, chalk dust, synthetic chemicals or just about anything you can imagine.

Step 2 - Close your eyes and get ready to concentrate.

Step 3 - This is the important part - Repeat out loud five times while turning counter-clockwise, "I am a scientific researcher practicing evidence-based medicine!" You must say this until you really, truly believe it. If you don't believe it strongly enough, the placebo effect will be ruined.

Step 4 - Thrust your palm in the direction of the placebo pills and shout, at the top of your voice, "You are now placebo!" You may feel a shiver of energy coursing through your body. That's the power of placebo reaching out to the pills.

The process is now complete. You may now use these placebo pills in any clinical trial and expect full approval of such use by your colleagues, famous medical journals and FDA regulators. (This is not a joke. This is the state of the art today in conventional medicine.)

Hope also has a huge role to place in all this. The more you hope your placebos are really placebos, the better results you'll get. In fact, in reporting on this whole fiasco, the lead researcher of the study uncovering all this, Dr Beatric Golomb, said, "We can only hope that this hasn't seriously systematically affected medical treatment."

But of course it has. (And by the way, no disrespect toward Dr Golomb. She deserves kudos for being willing to tackle this subject which will no doubt make her very unpopular among the cult of Scientism as practiced by conventional medical researchers today.)

How to improve your clinical trial results

For improved results, try to use the most harmful placebo substances you can. For example, in real clinical trials involving AIDS patients -- who tend to be lactose intolerant -- researchers have used pills made of, guess what? Lactose!

That's sort of like running a clinical trial on a cure for heroin addiction and using heroin as the placebo, isn't it? Gee, somehow our drug worked "better than placebo." Funny how that works, isn't it?

And if you still don't get the results you want, just start inventing your own data like other clinical trial researchers do. Remember Dr Scott Reuben? This highly-respected clinical trial researcher faked at least twenty-one clinical trials for Big Pharma (http://www.naturalnews.com/028194_S...). His fraudulent clinical trials are still being cited to sell prescription medications!

Heck, who needs placebo when you can just invent the data?

Come to think of it, who needs science when you can just use anything you want and call it placebo in the first place?

Conventional medicine operates clinical trials in the same way that banks and securities firms handle mortgage documents. They all just sort of make things up as they go along, committing felony crimes on a daily basis while hoping nobody notices. On that note, check out this amazing story by Greg Hunter called The Perfect No-Prosecution Crime (http://usawatchdog.com/the-perfect-...).

Where on the skeptics when it comes to Big Pharma science fraud?

Seriously, you just gotta love the state of medical science today. I've never watched a more hilarious group of nincompoops reassure each other that they're all so scientific while practicing the most quack-ridden chicanery imaginable. The stuff being pulled off today in the name of Big Pharma's clinical trials makes psychic detectives and tarot card readers look downright scientifically gifted by comparison.

It really makes you wonder about so-called "skeptics," doesn't it? If they're skeptical of homeopathy, tarot cards, psychic mediums and people who claim they can levitate, I can at least understand the urge to ask tough questions about all these things. I ask tough questions, too, especially when people tell me they've seen ghosts or spirits coming back from the dead or other unexplained phenomena. (And I've already publicly denounced so-called "psychic surgery" which it quite obviously little more than sleight-of-hand trickery combined with animal blood.)

But most conventional skeptics never step out of bounds of their "safety zone" of popular topics for which skepticism may be safely expressed. They won't dare ask skeptical questions about the quack science backing the pharmaceutical industry, for example. Nor will they ask tough questions about vaccines, or mammography, or chemotherapy. And you'd be hard pressed to find anything more steeped in outright fraudulent quackery than the pharmaceutical industry as operated today (and the cancer branch of it in particular).

That's why I'm skeptical about the skeptics. If a skeptic doesn't question the loosey goosey pseudoscience practiced by Big Pharma, then they really have no credibility as a skeptic. You can't be selectively skeptical about some things but then a fall-for-anything fool on other scams just because they're backed by drug companies.

But getting back to this study in particular...

Abstract of the study

Here's some of the text from the abstract of this study published in the Annals of Internal Medicine (http://www.annals.org/content/153/8...)

What's in Placebos: Who Knows? Analysis of Randomized, Controlled Trials

1. Beatrice A. Golomb, MD, PhD;
2. Laura C. Erickson, BS;
3. Sabrina Koperski, BS;
4. Deanna Sack, BS;
5. Murray Enkin, MD; and
6. Jeremy Howick, PhD

Background: No regulations govern placebo composition. The composition of placebos can influence trial outcomes and merits reporting.

Purpose: To assess how often investigators specify the composition of placebos in randomized, placebo-controlled trials.

Data Sources: 4 English-language general and internal medicine journals with high impact factors.

Study Selection: 3 reviewers screened titles and abstracts of the journals to identify randomized, placebo-controlled trials published from January 2008 to December 2009.

Data Extraction: Reviewers independently abstracted data from the introduction and methods sections of identified articles, recording treatment type (pill, injection, or other) and whether placebo composition was stated. Discrepancies were resolved by consensus.

Data Synthesis: Most studies did not disclose the composition of the study placebo. Disclosure was less common for pills than for injections and other treatments (8.2% vs. 26.7%; P = 0.002).

Limitation: Journals with high impact factors may not be representative.

Conclusion: Placebos were seldom described in randomized, controlled trials of pills or capsules. Because the nature of the placebo can influence trial outcomes, placebo formulation should be disclosed in reports of placebo-controlled trials.

Primary Funding Source: University of California Foundation Fund 3929 -- Medical Reasoning.


Labels: , , , , , , , , ,

Wednesday, December 1, 2010

Former Glaxo Lawyer Charged With Obstruction of Probe

The Wall Street Journal
November 2010
By THOMAS CATAN And PETER LOFTUS


Federal prosecutors charged a former GlaxoSmithKline PLC attorney with lying to obstruct a U.S. investigation into whether the pharmaceutical company illegally marketed an antidepressant as a weight-loss drug.

The Department of Justice on Tuesday indicted Lauren Stevens, a former vice president at the drug company, with four counts of making false statements to the Food and Drug Administration, as well as obstructing its investigation and withholding documents.

The indictment reflects a new U.S. effort to hold company executives legally accountable for criminal wrongdoing, rather than simply fining the companies for violations.

"This indictment shows that we will investigate those responsible for unlawful acts done on a company's behalf," said Richard DesLauriers, a special agent at the Federal Bureau of Investigation.

Ms. Stevens's lawyer said she did nothing wrong.

"Lauren Stevens is an utterly decent and honorable woman," Brien O'Connor said. "Everything she did in this case was consistent with ethical lawyering and the advice provided her by a nationally prominent law firm retained by her employer."

The indictment didn't identify the company or drug involved, but Glaxo confirmed that Ms Stevens formerly worked in its U.S. legal department and that the investigation involved its antidepressant Wellbutrin SR. It declined to comment further.

In its 2009 annual report, Glaxo disclosed that the government was inquiring about the company's response to an October 2002 letter from the FDA. The letter asked for information on the company's "alleged promotion of Wellbutrin SR for off-label use," meaning a use for which the drug didn't have FDA approval. Antidepressants have at times been associated with weight loss, though also with weight gain.

The U.S. attorney's office in Massachusetts has been leading a long-running investigation into Glaxo's marketing of several products between 1997 and 2004, including Wellbutrin SR, Glaxo has disclosed.

Glaxo first disclosed the existence of the investigation in 2004, and last year said it was taking a $400 million charge in relation to the probe, in a possible sign that it was approaching a settlement.

The Justice Department, acting on behalf of the FDA, has recently reached a slew of recent legal settlements with pharmaceutical companies for various violations, many of them prompted by information from whistleblowers.

Last month, GSK pleaded guilty to charges that it knowingly sold adulterated drugs made at its factory in Puerto Rico, paying $750 million in fines. The previous month, Allergan Inc. pleaded guilty to charges that the company actively promoted its top-selling product, the wrinkle-smoothing drug Botox, for unapproved medical uses such as treating headaches and pain. It paid $600 million to resolved the charges.

No individuals were indicted in those cases. To have an effective deterrent effect, the Justice Department has emphasized that it wishes to prosecute individual executives involved in corporate wrongdoing, so that the fines aren't simply seen as a cost of doing business.

The Wall Street Journal reported in March that the Food and Drug Administration planned to increase prosecutions of industry executives and corporate counsel.

Tuesday's indictment alleged that Ms. Stevens made a series of false statements and deliberately withheld potentially incriminating evidence from investigators. For example, she allegedly decided not to submit presentations made on the company's behalf by doctors who promoted the drug for unapproved purposes, prosecutors said.

A memorandum she requested to help decide whether she should hand over the slide sets warned that such a move would provide "incriminating evidence about potential off-label promotion of [the drug] that may be used against [the company] in this or in a future investigation," the indictment said.

Instead of providing the slides, Ms. Stevens wrote that the company's responses to the FDA's requests were "final" and "complete." The indictment says a company employee reported the alleged off-label promotion of the drug and sent the FDA some of the missing slides.
—Jeanne Whalen and Alicia Mundy contributed to this article.

Write to Thomas Catan at thomas.catan@wsj.com and Peter Loftus at peter.loftus@dowjones.com

Labels: , , , , , , , ,

Former Glaxo Lawyer Charged With Obstruction of Probe

Former Glaxo Lawyer Charged With Obstruction of Probe


By THOMAS CATAN And PETER LOFTUS

Federal prosecutors charged a former GlaxoSmithKline PLC attorney with lying to obstruct a U.S. investigation into whether the pharmaceutical company illegally marketed an antidepressant as a weight-loss drug.

The Department of Justice on Tuesday indicted Lauren Stevens, a former vice president at the drug company, with four counts of making false statements to the Food and Drug Administration, as well as obstructing its investigation and withholding documents.
The indictment reflects a new U.S. effort to hold company executives legally accountable for criminal wrongdoing, rather than simply fining the companies for violations.

"This indictment shows that we will investigate those responsible for unlawful acts done on a company's behalf," said Richard DesLauriers, a special agent at the Federal Bureau of Investigation.

Ms. Stevens's lawyer said she did nothing wrong.

"Lauren Stevens is an utterly decent and honorable woman," Brien O'Connor said. "Everything she did in this case was consistent with ethical lawyering and the advice provided her by a nationally prominent law firm retained by her employer."

The indictment didn't identify the company or drug involved, but Glaxo confirmed that Ms Stevens formerly worked in its U.S. legal department and that the investigation involved its antidepressant Wellbutrin SR. It declined to comment further.

In its 2009 annual report, Glaxo disclosed that the government was inquiring about the company's response to an October 2002 letter from the FDA. The letter asked for information on the company's "alleged promotion of Wellbutrin SR for off-label use," meaning a use for which the drug didn't have FDA approval. Antidepressants have at times been associated with weight loss, though also with weight gain.

The U.S. attorney's office in Massachusetts has been leading a long-running investigation into Glaxo's marketing of several products between 1997 and 2004, including Wellbutrin SR, Glaxo has disclosed.

Glaxo first disclosed the existence of the investigation in 2004, and last year said it was taking a $400 million charge in relation to the probe, in a possible sign that it was approaching a settlement.

The Justice Department, acting on behalf of the FDA, has recently reached a slew of recent legal settlements with pharmaceutical companies for various violations, many of them prompted by information from whistleblowers.

Last month, GSK pleaded guilty to charges that it knowingly sold adulterated drugs made at its factory in Puerto Rico, paying $750 million in fines. The previous month, Allergan Inc. pleaded guilty to charges that the company actively promoted its top-selling product, the wrinkle-smoothing drug Botox, for unapproved medical uses such as treating headaches and pain. It paid $600 million to resolved the charges.

No individuals were indicted in those cases. To have an effective deterrent effect, the Justice Department has emphasized that it wishes to prosecute individual executives involved in corporate wrongdoing, so that the fines aren't simply seen as a cost of doing business.

The Wall Street Journal reported in March that the Food and Drug Administration planned to increase prosecutions of industry executives and corporate counsel.

Tuesday's indictment alleged that Ms. Stevens made a series of false statements and deliberately withheld potentially incriminating evidence from investigators. For example, she allegedly decided not to submit presentations made on the company's behalf by doctors who promoted the drug for unapproved purposes, prosecutors said.

A memorandum she requested to help decide whether she should hand over the slide sets warned that such a move would provide "incriminating evidence about potential off-label promotion of [the drug] that may be used against [the company] in this or in a future investigation," the indictment said.

Instead of providing the slides, Ms. Stevens wrote that the company's responses to the FDA's requests were "final" and "complete." The indictment says a company employee reported the alleged off-label promotion of the drug and sent the FDA some of the missing slides.
—Jeanne Whalen and Alicia Mundy contributed to this article.

Write to Thomas Catan at thomas.catan@wsj.com and Peter Loftus at peter.loftus@dowjones.com

Labels: , , , , , ,

Drug Maker Wrote Book Under 2 Doctors Names, Documents Say

New York Times
By DUFF WILSON
November 29, 2010



Two prominent authors of a 1999 book teaching family doctors how to treat psychiatric disorders provided acknowledgment in the preface for an “unrestricted educational grant” from a major pharmaceutical company.


But the drug maker, then known as SmithKline Beecham, actually had much more involvement than the book described, newly disclosed documents show. The grant paid for a writing company to develop the outline and text for the two named authors, the documents show, and then the writing company said it planned to show three drafts directly to the pharmaceutical company for comments and “sign-off” and page proofs for “final approval.”

“That doesn’t sound unrestricted to me,” Dr. Bernard Lo, a medical ethicist and chairman of an Institute of Medicine group that wrote a 2009 report on conflicts of interest, said after reviewing the documents. “That sounds like they have ultimate control.”

The 269-page book, “Recognition and Treatment of Psychiatric Disorders: A Psychopharmacology Handbook for Primary Care,” is so far the first book among publications, namely medical journal articles, that have been criticized in recent years for hidden drug industry influence, colloquially known as ghostwriting.

“To ghostwrite an entire textbook is a new level of chutzpah,” said Dr. David A. Kessler, former commissioner of the Food and Drug Administration, after reviewing the documents. “I’ve never heard of that before. It takes your breath away.”

The book has never been in wide circulation and has not been sold for a few years. Guidelines restricting the use of industry money to support medical journal articles or doctors’ research have come into wide acceptance within the last several years, to try to minimize the influence of companies’ marketing on medical practices.

The book’s listed co-authors were Dr. Charles B. Nemeroff, chairman of psychiatry at the University of Miami medical school since 2009 and Emory University before that, and Dr. Alan F. Schatzberg, who was chairman of psychiatry at the Stanford University School of Medicine from 1991 until last year.

The letter documenting the relationship between Dr. Nemeroff, a writing company and SmithKline was dated Feb. 4, 1997. It and a “preliminary draft” of the book, dated Feb. 21, 1997, and adding Dr. Schatzberg’s name were released Monday by the Project on Government Oversight, a Washington advocacy group. They were attached to a letter of complaint to Dr. Francis S. Collins, director of the National Institutes of Health. In the letter, Danielle Brian, executive director of the project, and Paul Thacker, an investigator, formerly with the staff of Senator Charles Grassley of Iowa, also cited other examples of what they termed ghostwriting and asked the N.I.H. for better policing of such practices.

The documents were separately obtained by The New York Times from the Los Angeles law firm of Baum Hedlund, which received them as part of discovery in lawsuits against the drug company, now known as GlaxoSmithKline, involving Paxil. Leemon B. McHenry, a bioethicist with California State University, Northridge, who consults for the law firm, said many similar documents remain sealed. “This is only the tip of the iceberg,” he said.

Responding to questions by e-mail last week, Dr. Nemeroff and Dr. Schatzberg emphasized the “unrestricted” nature of the grant from the drug maker to develop the book and said they did most of the work. SmithKline “had no involvement in content,” Dr. Schatzberg said, adding, “An unrestricted grant does not give the company any right of sign-off on content and in fact they had no sign-off in content.”

Dr. Nemeroff said he and Dr. Schatzberg “conceptualized this book, wrote the original outline and worked on all of the content.”

But the writing company, Scientific Therapeutics Information of Springfield, N.J., had developed “a complete content outline” for Dr. Nemeroff’s comment, according to the 1997 letter from one of the company’s officials. The company also said it had “begun development of the text.” The writing company did not respond to requests for comment.

Kevin G. Colgan, a spokesman for GlaxoSmithKline, said the company’s role in the book was described in its preface. In recent years, he added, the company has tightened its internal guidelines for medical writers.

Ron McMillen, chief executive of American Psychiatric Publishing, which published the book, said he reviewed files on it Monday and found no evidence of influence by the writing company or GlaxoSmithKline. But Mr. McMillen also said he had been unaware of the plan outlined in the two-page letter to Dr. Nemeroff.

“This would show more involvement than we would accept,” he said after reviewing it.

The book sold about 26,000 copies, including 10,000 bought by SmithKline Beecham for American family doctors and 10,000 purchased by the Dutch pharmaceutical company Organon, Mr. McMillen said. The authors together received a 15 percent royalty of the $120,000 sales, or about $18,000, he said.

Since there are about 100,000 family physicians in the United States, the book reached only a small percentage of them and has probably declined in usage since 1999. Dr. Howard A. Brody, an author, blogger and professor of family medicine at the University of Texas Medical Branch at Galveston, speculated that family doctors may have had some resistance to a book from a psychiatric press.

Mr. McMillen said the book was co-published with the American Medical Association. He said it was distributed until a few years ago.

Dr. Nemeroff said the book was written to fill an unmet need in educating family doctors and primary care physicians on how to provide adequate treatment for people with mental illness. “Remarkably, the book remains quite accurate and relevant to clinical practice today,” he said.

Dr. Nemeroff said he and Dr. Schatzberg “scrutinized every page and rewrote and edited as we deemed necessary,” keeping control of the final draft.

Dr. Schatzberg said he had not seen the 1997 letter to Dr. Nemeroff. He termed it “a theoretical proposal that bears little, if any relationship to what actually happened.”

Dr. Lo, who is a professor of medicine and director of the medical ethics program at the University of California, San Francisco, said that medical textbooks and handbooks should make it clear — as peer-reviewed journals now do — whose idea it was, who wrote the first draft, and who edited. Dr. Lo and other experts said ghostwriting has receded in recent years with tougher journal standards.

Dr. Nemeroff and Dr. Schatzberg have been listed on other titles, including co-editors of the Textbook of Psychopharmacology, a book for psychiatrists and medical students, whose third edition appeared in 2003. In 2008, Emory University imposed a two-year ban on Dr. Nemeroff receiving N.I.H. grants after a Senate inquiry found that he had failed to disclose at least $1.2 million in industry financing over seven years from pharmaceutical companies, including GlaxoSmithKline.

This article has been revised to reflect the following correction:

Correction: December 1, 2010

An article on Tuesday about a drug maker’s involvement in writing a 1999 book that teaches family doctors how to treat psychiatric disorders misstated, in some editions, part of the curriculum vitae of Dr. Charles B. Nemeroff, one of the doctors whose names appeared as authors of the volume. He was once a psychiatry professor at Emory University, not Tulane University.
A version of this article appeared in print on November 30, 2010, on page B3 of the New York edition.

Labels: , , , , , , , , , ,